Paul H Naylor

US Patent:

20050148538, Jul 7, 2005

Filed:

Jul 26, 2002

Appl. No.:

10/500602

Inventors:

John Hadden - Cold Springs Harbor NY, US
Paul Naylor - Lindenhurst NY, US
Kathy Signorelli - Kings Park NY, US

International Classification:

A61K031/7076
A61K039/00
A61K039/38
A61K039/12
A61K039/02

US Classification:

514045000, 424184100, 424204100, 424234100

Abstract:

A pharmaceutical composition including an adjuvant effective amount of a protected inosine monophosphate (IMP) compound. The pharmaceutical composition includes the protected IMP compound alone, or in combination with vaccine agents with or without additional adjuvants. The pharmaceutical composition can be utilized as a vaccine composition or can be included with existing vaccine compositions in order to increase a specific T lymphocyte mediated immune response thereto. Various methods relating to the pharmaceutical composition and N the vaccine are described herein. The vaccines can be employed to prevent or treat infections. Additionally, the pharmaceutical compositions not only increase T-cell responses, but also confer, by pretreatment, non-specific protection against a variety of pathogens. This combination of actions is appropriate for enhancing defense against bioterrorism with organisms like smallpox or anthrax.

US Patent:

20110076249, Mar 31, 2011

Filed:

Dec 3, 2010

Appl. No.:

12/960130

Inventors:

John W. Hadden - Cold Spring Harbor NY, US
Paul Naylor - Farmingdale NY, US

Assignee:

IRx Therapeutics, Inc. - New York NY

International Classification:

A61K 38/20
A61K 31/192
A61K 31/405
A61K 31/66
A61K 38/19
A61K 38/21
A61P 29/00
A61P 35/00
A61P 31/00

US Classification:

424 852, 514576, 514420, 514110, 514 11, 424 855, 424 857

Abstract:

The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and/or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of treating these cellular immunodeficiencies using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (NSAID). The invention also provides a diagnostic skin test comprising NCM for predicting treatment outcome in cancer patients.

US Patent:

20120064035, Mar 15, 2012

Filed:

May 17, 2010

Appl. No.:

13/320584

Inventors:

John W. Hadden - Cold Spring Harbor NY, US
Kathy Signorelli - Kings Park NY, US
James Egan - Farmingdale NY, US
Paul Naylor - Farmingdale NY, US

Assignee:

IRX Therapeutics, Inc. - New York NY

International Classification:

A61K 38/21
A61P 37/04
A61P 35/00

US Classification:

424 852

Abstract:

A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.

US Patent:

20130171192, Jul 4, 2013

Filed:

Oct 23, 2012

Appl. No.:

13/658518

Inventors:

Paul H. Naylor - Hazel Park MI, US

Assignee:

IRX Therapeutics, Inc. - New York NY

International Classification:

A61K 39/39

US Classification:

4242081, 4241841, 4242041, 4242341, 4242651, 4242461, 4242111

Abstract:

A pharmaceutical composition including an adjuvant effective amount of a protected inosine monophosphate (IMP) compound. The pharmaceutical composition includes the protected IMP compound alone, or in combination with vaccine agents with or without additional adjuvants. The pharmaceutical composition can be utilized as a vaccine composition or can be included with existing vaccine compositions in order to increase a specific T lymphocyte mediated immune response thereto. Various methods relating to the pharmaceutical composition and the vaccine are described herein. The vaccines can be employed to prevent or treat infections. Additionally, the pharmaceutical compositions not only increase T-cell responses, but also confer, by pretreatment, non-specific protection against a variety of pathogens. This combination of actions is appropriate for enhancing defense against bioterrorism with organisms like smallpox and anthrax.

US Patent:

20130243723, Sep 19, 2013

Filed:

Feb 20, 2013

Appl. No.:

13/771622

Inventors:

Kathy L. Signorelli - Kings Park NY, US
James E. Egan - Stony Brook NY, US
Paul H. Naylor - Lindenhurst NY, US

Assignee:

IRX Therapeutics, Inc. - New York NY

International Classification:

A61K 39/39
A61K 39/395
A61K 45/06

US Classification:

424 852

Abstract:

A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.

US Patent:

45433402, Sep 24, 1985

Filed:

Apr 7, 1983

Appl. No.:

6/482384

Inventors:

Allan L. Goldstein - Washington DC
Teresa L. K. Low - Annandale VA
John McClure - Houston TX
Paul H. Naylor - Bowie MD

Assignee:

George Washington University - Washington DC

International Classification:

G01N 3356
A61K 3900
C07G 700
C07C10352

US Classification:

436542

Abstract:

A radioimmunoassay for the polypeptide thymic hormone thymosin. beta. sub. 4 is described. The assay employs a radiolabelled Tyr-C13-thymosin. beta. sub. 4 -analogue as probe and a thymosin. beta. sub. 4 antibody.